Suraksha Diagnostic Ltd Q1 FY26 – ₹72.6 Cr Revenue, ₹9.4 Cr PAT, P/E 49.3: Can Bengal’s Testing Kingpin Survive a National Rollout Without Flatlining?
1. At a Glance
Kolkata’s favorite needle-poking, scan-clicking, report-churning diagnostic chain just coughed up numbers: ₹72.6 Cr revenue, ₹9.4 Cr PAT, and a spicy P/E of 49.3. The business looks like a glucose report—sugar high but needs insulin soon. With 6.69 million tests last year, Suraksha is basically the Adda of pathology in Bengal. But can a company 100% dependent on West Bengal’s hypochondriac population become “India’s Dr. Lal”? Or is it just another case of local hero, national zero?
2. Introduction
Let’s get this straight—diagnostic companies are basically WhatsApp groups with a blood centrifuge. Everyone’s in it, nobody leaves, and once you’re stuck, your health records ensure repeat business. Suraksha Diagnostic, born in 2005, mastered this formula in West Bengal by offering 2,300+ tests that range from the boring (hemoglobin) to the scary (oncology panels that sound like alien passwords).
Their moat? A hub-and-spoke model that sounds fancy but is just “central lab + satellites + small collection centers.” Efficiency? Sure. Sexy? Only if you’re into refrigerated vans carrying your auntie’s sugar sample.
Now, the big drama: they IPO-ed in Dec 2024, raising ₹846 Cr, only to discover that public scrutiny is more brutal than a colonoscopy. Add to that—EBITDA per patient is ₹715, revenue per patient ₹2,118. So yes, they make ~34% margin while smiling in white coats. The question is, how long before competition from Dr. Lal, Metropolis, and Vijaya Diagnostic injects some real pain?
3. Business Model – WTF Do They Even Do?
If you thought they just run pathology labs, think again. Suraksha has three main money-printing machines:
Pathology (50.81%) – The good old blood, urine, and stool business. (And no, your sample is not stored in a locker like your old physics notes.)
Radiology (45.22%) – X-ray, CT scan, MRI—basically, they charge you for lying still inside a giant humming donut.
Doctor Consultation (3.97%) – The smallest slice, but they flex 1,000+ doctors on their roster. Half of them probably spend their day saying “drink more water.”
The model is B2C heavy (93%), meaning your neighborhood hypochondriac uncle is the primary revenue source, not hospitals or corporates. Smart? Yes, because individuals panic-order more tests than corporates ever will. Risky? Also yes, because Bengal’s population growth is slower than their internet speed.
Oh, and about their trademark—“Suraksha” isn’t even registered in their name. Imagine building a ₹1,640 Cr market cap empire and realizing someone else owns your surname. That’s like Virat Kohli discovering his Instagram handle belongs to a fan page.
4. Financials Overview
Metric
Latest Qtr (Q1 FY26)
Same Qtr Last Yr
Prev Qtr
YoY %
QoQ %
Revenue
₹72.6 Cr
₹60.7 Cr
₹65.1 Cr
19.5%
11.5%
EBITDA
₹23.7 Cr
₹20.6 Cr
₹19.2 Cr
15.0%
23.7%
PAT
₹9.4 Cr
₹7.7 Cr
₹7.2 Cr
22.1%
30.6%
EPS (₹)
1.80
1.84
1.42
-2.2%
26.8%
Commentary: Revenue grew faster than the BMI of a teenager on Maggi. QoQ PAT growth of 30% looks heroic, but EPS YoY dipped because the IPO diluted shares—classic OFS hangover. P/E at 49.3? That’s the price of premium gym membership while you still eat momos outside the lab.
Question to readers: Would you pay 50x earnings for a company whose entire patient base is in Bengal?
